title: [Analysis of neuromuscular blocking drugs and sugammadex expenses, one year after its introduction into routine clinical practice].
authors.forename: J
authors.initials: J
authors.lastname: Raft
authors.forename: E-D
authors.initials: ED
authors.lastname: Chenot
authors.forename: D
authors.initials: D
authors.lastname: Longrois
authors.forename: C
authors.initials: C
authors.lastname: Meistelman
mesh_terms: D000768:Anesthesia, General / Q000191:economics; D002800:Cholinesterase Inhibitors / Q000191:economics; D003362:Cost-Benefit Analysis; D004363:Drug Utilization; D006801:Humans; D009388:Neostigmine / Q000191:economics; D003473:Neuromuscular Nondepolarizing Agents / Q000037:antagonists & inhibitors / Q000191:economics*; D000077122:Sugammadex; D047408:gamma-Cyclodextrins / Q000191:economics*
chemical_list: D002800:Cholinesterase Inhibitors; D003473:Neuromuscular Nondepolarizing Agents; D047408:gamma-Cyclodextrins; D000077122:Sugammadex; D009388:Neostigmine